HUE033204T2 - Faktor II önmagában vagy további faktorral kombinálva, hígulásos koagulopátiával összefüggõ károsodott hemosztázis kezelésére - Google Patents
Faktor II önmagában vagy további faktorral kombinálva, hígulásos koagulopátiával összefüggõ károsodott hemosztázis kezelésére Download PDFInfo
- Publication number
- HUE033204T2 HUE033204T2 HUE11761051A HUE11761051A HUE033204T2 HU E033204 T2 HUE033204 T2 HU E033204T2 HU E11761051 A HUE11761051 A HU E11761051A HU E11761051 A HUE11761051 A HU E11761051A HU E033204 T2 HUE033204 T2 HU E033204T2
- Authority
- HU
- Hungary
- Prior art keywords
- obb
- fii
- fibrinogen
- blood
- fviia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Claims (5)
- Γ*Κϊι>»ΙΙΟΝΜ««*Η*\\ UH ÍOV\B«lF\MOKOfcA\t Μ>Μ*ίϊ\,Μ \ \-Η«,Ι ? s$On kOW^U^AHU Μ yV^/JFi ΟΟΟ ΚΛΗΟΝ,ΟίΚΗί Hl MOS' ί SÍI*· ΚΙ £Μ f XFRν |Mfcsi|^Í8» ifF8f pímíöfe S v Aivadáslíákm^k^HH, amely » köveítebk M«;y W§í áll: i; > kik vagy i "í i U i \ Μ X S í X UmS'Ci;,^ a\\V, S,ígV i.'! fibdm*gá« és Fii FVfla és. FX kíí?8kls^l|i:A ^y (4.j fibrtrsogén és Fék vagy vagv (F); tibisöpíi FH #S fVíU » í í s v V ., 1V „ s s SS·. H| i V ss * , s. s > i s JV Tk 5 V s ts í V ateknaáSü^. k \h V'aiiv vVss'V-yv^ag ,. m . k-A,!H \«k isO>whOO all {OFlLvsgy ('·) Fii FV Oá és FX konHFoaeióyy v agy (3? fsbrioogé» ás Fii FVUa es FX kombinációja, vagy (4 j Fibrinogen és Hl, vagy CH FH é? FViía, vagy (6! übrioogén. FH ás FVIH, ihi'«ulá$os kösgísiorásiiiva'· össreilíggb kávásodon bemossíáxilbsb sesfivsdb es8iö$bé8; á; maximáld, a:, HFksí dard,-ag íMCÍ » Í\oc':cjd't'0 ΙΗίνΒν alFaimaeVana
- 3. Aiv a kbvelkexdk bármelyikéből |!|; (í i Hi, vagy (2d Fii, F'V'iKt és FX kombinációja, vagy Hí íibrimígFicsk Ili FVíía és FX knmbbvklfjá, >a|iy (4) Ohrinogén és FH, vagy (S í Fii és FVÍks, vagy H5' ííbrmoa''8, i iiv. k\ lk5 hígaOv·* koagük'poS'avoi várnia >v Loosodob í om --10.Hars o-vased" 'cd v-ben s s,-Ό ,, κ- η-- Η Η ϊ csökkentésében Hnend aikaimaaáí ra.
- 4. AiVagg,,;faklor-kv ?e ie s. amtdy a kOveiXsabk bármely lkából áli (i,i Hi. vagy Hí i ii F\ ligás FX kombinációja, vagy Hí ftbrmogsm ex FH. FVHaéx FX konthrnóbíSfá sags O" oí"'í SvO>slH >,,vv (S> Hí és kVIlíg vagy léi bbHnogéo, Hí és FViia, blksltlsOx bssxHiSggi; fefessílöi::.i:te©^2^ssMn. i?|lgVs$&:8: IÍ?s^!ÍMpÍí||s: >'vba.nb<n Mseik Hko.ío l\a' í 5. A?. M. >g«nvpo8tok· bJník'íyü^ szcTíiiíi »i\ndási&l tor-kcf^éi. az m megHatároxott alkl!í$g$|.&% :^§ sz Hl rhHt «* 1-tC* m#k*>l6mbaa bossioik
- 6, Ax |-5. i>><síϊv}>í>ísSisk bármelyike s»vsbál aivas&ss faktorkcxeko. a.>: ο». megbatározott alkalmadra, a higuiáxos ks>sgsslefáiiávsb bss2®%gb Mrasssibb Κακοβϋ&χρ jelelik Vérveszteséggel fógg 9¾ például MMxen beavstkossás kdrdb. seb-ésxe» beavaütnxá* ιϋ&η vMfed vagy ptíMpastussv homon'hádávd bsvxeAiggöjdémbs vósv®M®sá|pb % Az Ml igénypontok kársnetyite sxetltó atkalmwásra* áboilsx Fik FVÍI& vagy FX tü (slMl), tblombmáns FVíta (rhkVib? vagy rekombinám, IX (rhldO. 8 Αχ:;:Mí. ipán pontok bármelyike s^riml aiv-adásifaktor-kexeiév az őrt megbatározott aik&Sma&bm. ahol a fexelásí-e ssüi'dó emlős ftbtníog-.'okciocínirásc'tójáftak Némáimra kevesebb. mint mitaegy 2 y k keltebb, roM mintegy Ig4 keyssobfe, mim mls%y:l>d g- b kevesebb, mint mintegy 200 mgrdi, kevesebb, mint nüm<?£. ISO mg/db kevesebb, mid mintegy I<j0 mgM? vagy kevesebb, mim mmtegy Mi bt|/di: % Az i-k, lgd»^®»5töfe?%ár^IÍ5fe: saserinti aHad&tiaMor-kexefcis ax ott meg&asmwott aikaímaxástn, shoi & károsodon herooMábs egy emlős beebtfi teljes véstérfe|ístásak spiMegy 10%-áosi nagyobb, mintegy .tÖ’Másvá! nagyobb, mintegy SÖ^ánál Hrgpbiy mmiegy őWv-gtsái :sagy«b% mtótogy 70%-áoá^ napobb, ív ,v.v 50V ,η,άΗοί. >o,*' , m v 'n M^ ;>· v<i''! ' >, -< 'v^ ük A 0. igénypont szermti stvud&sitákfookezeiés az no mcKharitoísrU. ,»iksiötazSsr%:,aboI>» liipj^»s;:. ku&gukspátb nomtovolémia viasxaáSlitáNifcól va&\ h&irwihm^jM8ÍM®mámö^miL·. U. Ax MC*. igénypontok bármelyik* semmis d vMá5Mktor4e,Mós sm ott snegteMrosod (bkaMMíMi, ah»! olyan menny Myben adunk be fibrkmngém, smHy «iegtxstfc a vét fibríöt^.fcoöceairáci^ának mimegy -Öi5 gA-tniniegy·1 §&-mintegy 1,5 g.A vagy-mmtegy 2 mgd iíM* emeléséhez.
- 12. Ax HU. igénjpontok bánod) ike t-zerinti dvadássibktor-ke?®ies a? ott niegteüámeou atkaimaxasra, nhol o fibrinogen 12;5HÍÍ10 mg/kg doxixixiu boadotb JX Az M2. ípuypootok bámielyiks szeriníi <dv&<tóij.irakrur*k«xeiéx az ott abo? ü.í atva:ias»Mn>r-kwekb; olyan dógixban beabotk smeiy mintegy 4(Msö ukiaMporocei cxkkkvob 3?. ;dvadás; (dot. .x;xd> mnm'gt W A «rm-A rmh a ma'.nwK aK.Kkk'od.odx«\-f. oa v.^ a Oo.ake, man k-pbtbb UX óráig íKsroorbxán koasniávk; fennmaradásár eredmssjyezi. i4 Αϋ Fi.5 tM>oo{.xokok hárbndspo ^xibu. oXadasdakiui.koruké ac· on (OoH'oíoíoxoís ,d ό .λ ; alsói |κ aiyidiáailaktof-kexolós (iy fíí.tFVlbí by bX kooiblf.áoiéá& vagy f.>) Ft!. FVÍfa óv i'X kombinslcitita dH.oogvr.oob ev .not .to t H vo i'X bo kyak'^b ; '-Hi .uo>oK«> l robots :15. Az Mo. ígéovposHok bóstuolyikv ssrlstiFskvadasibiktor-keioid;; a? ou usoghosároxot; atkaimazsism. :íÉöí;^:áivadávitaktOí-Wela§ ü> pll vagy (4) kbnssogáo Hl-
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39022410P | 2010-10-06 | 2010-10-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE033204T2 true HUE033204T2 (hu) | 2017-11-28 |
Family
ID=44677879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE11761051A HUE033204T2 (hu) | 2010-10-06 | 2011-09-19 | Faktor II önmagában vagy további faktorral kombinálva, hígulásos koagulopátiával összefüggõ károsodott hemosztázis kezelésére |
Country Status (16)
Country | Link |
---|---|
US (1) | US9433664B2 (hu) |
EP (1) | EP2624859B1 (hu) |
JP (1) | JP6000259B2 (hu) |
KR (1) | KR20130136988A (hu) |
CN (1) | CN103221061A (hu) |
AU (1) | AU2011313505B2 (hu) |
BR (1) | BR112013008034A2 (hu) |
CA (1) | CA2812888A1 (hu) |
DK (1) | DK2624859T3 (hu) |
ES (1) | ES2625153T3 (hu) |
HU (1) | HUE033204T2 (hu) |
MX (1) | MX343784B (hu) |
PL (1) | PL2624859T3 (hu) |
RU (1) | RU2606155C2 (hu) |
SG (2) | SG10201508159SA (hu) |
WO (1) | WO2012045569A1 (hu) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103221061A (zh) | 2010-10-06 | 2013-07-24 | 米迪缪尼有限公司 | 用于治疗止血障碍的因子ii以及纤维蛋白原 |
IL230150A0 (en) | 2013-12-24 | 2014-09-30 | Omrix Biopharmaceuticals Ltd | One-component fibrin glue containing zymogens |
EP3579857B1 (en) * | 2017-02-09 | 2022-04-06 | CSL Behring GmbH | A blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings |
CN116059431A (zh) * | 2021-10-29 | 2023-05-05 | 丁琴琴 | 一种含凝血因子的双层止血敷料及其制备方法 |
WO2023220412A1 (en) * | 2022-05-13 | 2023-11-16 | Cedars-Sinai Medical Center | Hemostatic monitor |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0686385B2 (ja) | 1980-01-28 | 1994-11-02 | バクスタ−、インタ−ナショナル、インコ−ポレイテッド | 活性プロトロンビン複合体組成物およびその製造方法 |
US4501731A (en) | 1983-06-27 | 1985-02-26 | Tishkoff Garson H | Treatment of disparate bleeding disorders with factor X zymogen |
DE4430204A1 (de) * | 1994-08-26 | 1996-02-29 | Behringwerke Ag | Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung |
DK0796623T3 (da) | 1996-03-20 | 2005-08-01 | Baxter Ag | Farmaceutisk præparat til behandling af blodkoagulationslidelser |
AT409334B (de) | 1997-09-19 | 2002-07-25 | Immuno Ag | Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren |
US7094428B2 (en) | 2000-06-16 | 2006-08-22 | The University Of Medicine And Dentistry Of New Jersey | Hemostatic compositions, devices and methods |
US6825323B2 (en) | 2001-01-10 | 2004-11-30 | The United States Of America As Represented By The Secretary Of The Army | Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same |
CA2437015A1 (en) | 2001-02-05 | 2002-08-15 | Novo Nordisk Health Care Ag | Combined use of factor vii polypeptides and factor ix polypeptides |
US20060025336A1 (en) | 2001-07-16 | 2006-02-02 | Novo Nordisk A/S | Pharmaceutical compositions comprising combinations of factor VII polypeptides and aprotinin polypeptides |
KR20040015821A (ko) * | 2001-07-20 | 2004-02-19 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 인자 ⅶ 폴리펩티드와 인자 ⅹⅰ폴리펩티드를 포함하는약학적 조성물 |
US20040101546A1 (en) | 2002-11-26 | 2004-05-27 | Gorman Anne Jessica | Hemostatic wound dressing containing aldehyde-modified polysaccharide and hemostatic agents |
NZ541489A (en) | 2002-12-31 | 2011-06-30 | Marinepolymer Tech Inc | Topically applied vasoconstrictor for treatment in cardic catheterization complications |
GB0324044D0 (en) * | 2003-10-14 | 2003-11-19 | Astrazeneca Ab | Protein |
US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
WO2005117912A1 (en) | 2004-05-27 | 2005-12-15 | Avigen, Inc. | Methods for treating bleeding disorders using sulfated polysaccharides |
US20080188400A1 (en) | 2005-04-26 | 2008-08-07 | Maxygen Holdings Ltd. | Methods For Treating Bleeding |
MX336958B (es) | 2005-11-15 | 2016-02-05 | Philadelphia Children Hospital | Metodos y composiciones para modular la hemostasia. |
JP2009528843A (ja) * | 2006-03-06 | 2009-08-13 | ヒューマジーン・インコーポレイテッド | 組換えヒトトロンビンおよびフィブリノゲンの調製法 |
US20080014251A1 (en) | 2006-07-14 | 2008-01-17 | Advanced Vascular Dynamics | Hemostatic compound and its use |
WO2008051513A2 (en) | 2006-10-23 | 2008-05-02 | Allan Pronovost | Compositions and methods for treating lacerations, abrasions, avulsions, burns, ulcers, and cases of excessive bleeding |
EP1935429A1 (en) * | 2006-12-22 | 2008-06-25 | CSL Behring GmbH | Synergistic therapeutic use of prothrombin complex concentrates with FVIII concentrates |
WO2008121330A1 (en) | 2007-03-30 | 2008-10-09 | Thrombodyne, Inc. | Methods of making concentrated fibrinogen containing compositions and associated systems for preparing fibrin glue |
UA101155C2 (ru) | 2007-04-13 | 2013-03-11 | Каталист Байосайенс, Инк. | Модифицированный полипептид фактора vii (fvii) и его применение |
US8852558B2 (en) | 2008-03-11 | 2014-10-07 | Materials Modification, Inc. | In situ formation of an artificial blockage to control bleeding by polymer expansion with hydrogen peroxide and platinum catalyst |
CA2740079A1 (en) | 2008-10-08 | 2010-04-15 | Thrombodyne, Inc. | Methods of making concentrated fibrinogen- and platelet-containing compositions |
CN103221061A (zh) | 2010-10-06 | 2013-07-24 | 米迪缪尼有限公司 | 用于治疗止血障碍的因子ii以及纤维蛋白原 |
-
2011
- 2011-09-19 CN CN2011800479754A patent/CN103221061A/zh active Pending
- 2011-09-19 RU RU2013120033A patent/RU2606155C2/ru not_active IP Right Cessation
- 2011-09-19 BR BR112013008034A patent/BR112013008034A2/pt not_active IP Right Cessation
- 2011-09-19 PL PL11761051T patent/PL2624859T3/pl unknown
- 2011-09-19 JP JP2013532104A patent/JP6000259B2/ja not_active Expired - Fee Related
- 2011-09-19 EP EP11761051.9A patent/EP2624859B1/en not_active Revoked
- 2011-09-19 MX MX2013003715A patent/MX343784B/es active IP Right Grant
- 2011-09-19 DK DK11761051.9T patent/DK2624859T3/en active
- 2011-09-19 HU HUE11761051A patent/HUE033204T2/hu unknown
- 2011-09-19 CA CA2812888A patent/CA2812888A1/en not_active Abandoned
- 2011-09-19 SG SG10201508159SA patent/SG10201508159SA/en unknown
- 2011-09-19 ES ES11761051.9T patent/ES2625153T3/es active Active
- 2011-09-19 AU AU2011313505A patent/AU2011313505B2/en not_active Ceased
- 2011-09-19 WO PCT/EP2011/066241 patent/WO2012045569A1/en active Application Filing
- 2011-09-19 US US13/877,854 patent/US9433664B2/en not_active Expired - Fee Related
- 2011-09-19 KR KR1020137008520A patent/KR20130136988A/ko not_active Application Discontinuation
- 2011-09-19 SG SG2013021498A patent/SG188639A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2013003715A (es) | 2013-09-26 |
AU2011313505B2 (en) | 2015-09-17 |
KR20130136988A (ko) | 2013-12-13 |
WO2012045569A9 (en) | 2016-01-07 |
RU2013120033A (ru) | 2014-11-20 |
US20130280236A1 (en) | 2013-10-24 |
PL2624859T3 (pl) | 2017-09-29 |
DK2624859T3 (en) | 2017-06-06 |
ES2625153T3 (es) | 2017-07-18 |
CN103221061A (zh) | 2013-07-24 |
EP2624859A1 (en) | 2013-08-14 |
RU2606155C2 (ru) | 2017-01-10 |
BR112013008034A2 (pt) | 2016-06-14 |
JP2013538863A (ja) | 2013-10-17 |
WO2012045569A1 (en) | 2012-04-12 |
EP2624859B1 (en) | 2017-03-01 |
SG10201508159SA (en) | 2015-10-29 |
CA2812888A1 (en) | 2012-04-12 |
US9433664B2 (en) | 2016-09-06 |
MX343784B (es) | 2016-11-23 |
AU2011313505A1 (en) | 2013-04-11 |
SG188639A1 (en) | 2013-05-31 |
JP6000259B2 (ja) | 2016-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Moore et al. | Does tranexamic acid improve clot strength in severely injured patients who have elevated fibrin degradation products and low fibrinolytic activity, measured by thrombelastography? | |
ERIKSEN et al. | Mechanisms of hydroxyethyl starch‐induced dilutional coagulopathy | |
Fries et al. | Efficacy of fibrinogen and prothrombin complex concentrate used to reverse dilutional coagulopathy—a porcine model | |
Remuzzi et al. | Role of endothelium-derived nitric oxide in the bleeding tendency of uremia. | |
Dickneite et al. | Animal model and clinical evidence indicating low thrombogenic potential of fibrinogen concentrate (Haemocomplettan P) | |
Mitterlechner et al. | Prothrombin complex concentrate and recombinant prothrombin alone or in combination with recombinant factor X and FVIIa in dilutional coagulopathy: a porcine model | |
Solomon et al. | Fibrin formation is more impaired than thrombin generation and platelets immediately following cardiac surgery | |
Schulman | Pharmacologic tools to reduce bleeding in surgery | |
JPS58500994A (ja) | 止血用医薬組成物 | |
ES2230624T3 (es) | Composicion farmaceutica que comprende un compuesto que tiene actividad anti-xa y un compuesto antagonista de la agregacion plaquetaria. | |
Honickel et al. | Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model | |
Woessner et al. | Influence of a long-term, high-dose volume therapy with 6% hydroxyethyl starch 130/0.4 or crystalloid solution on hemodynamics, rheology and hemostasis in patients with acute ischemic stroke: Results of a randomized, placebo-controlled, double-blind study | |
US20100279939A1 (en) | Recombinant human fibrinogen for treatment of bleeding in trauma and platelet disorders | |
EP2624859B1 (en) | Factor ii alone or in combination with further factors for treatment of impaired haemostasis associated with dilutional coagulopathy | |
CN102088999A (zh) | 用于治疗凝血细胞抑制剂诱导的凝血病的血管假性血友病因子或因子viii和血管假性血友病因子 | |
Kalbhenn et al. | Bleeding during veno-venous ECMO: prevention and treatment | |
Rogers et al. | Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis | |
Favaloro et al. | Editorial compilation X | |
JP2012519674A (ja) | フィブリノーゲンの新規な使用 | |
CN110114074A (zh) | 用于治疗或预防出血的凝血因子替代产品 | |
Zhao et al. | Efficacy of erythropoietin combined with tranexamic acid in reducing perioperative blood loss and blood transfusion rate in elderly patients with femoral intertrochanteric fractures | |
Bauer et al. | Monitoring of heparin therapy and establishment of an optimal therapy scheme for thrombosis prophylaxis in a pig model for human catheter interventions | |
Arshad | Pathophysiology and management of hemostatic alterations in cirrhosis and liver transplantation | |
Parameswaran et al. | The use of recombinant factor VIIa in gastrointestinal bleeding | |
Maxwell et al. | Motoyama & Davis: Smith's Anesthesia for Infants and Children |